Are you a registered HCP in India?
Yes
No
Lorem ipsum dolor sit amet consectetur adipisicing elit.
I Consent
Disclaimer
This presentation is intended for educational and informational purposes only. Though the presentation has been prepared by taking care and placing reliance on substantiable sources, Novartis does not assume responsibility for any information not being accurate, complete OR for any change in the information or data post preparation of the presentation.

Further, any independent content, views, thoughts and experiences of the presenter are personal to him/her and Novartis does not take any accountability or responsibility for the views and opinions expressed by the presenter. Such personal views, thoughts, content etc. do not necessarily reflect Novartis’ position, policies or views and Novartis does not necessarily endorse, certify, or guarantee the accuracy, completeness, or reliability of  such independent  information  presented. The presenter is solely responsible for obtaining the necessary permissions and licenses to use any photos, videos, or any other items added by him/her. Novartis does not assume any liability whatsoever, for the content, views, guidance, as well as any infringement of intellectual property rights by the presenter.

Novartis does not recommend the use of its products in unapproved indications, dosage  and recommends to refer to complete prescribing information prior to using any of the Novartis products
OK
Welcome to the Knowledge Portal
Select an option for a tool box
LDL-Connect
Lp(a) Connect
LDL-Connect Lp(a) Connect
A practical approach to help your patients achieve their LDL-C goal & reduce their CV risk

LDL-C & ASCVD

Early LDL-C lowering reduces ASCVD risk in India.

Guideline LDL-C targets

Latest guidelines: < 55 mg/dL LDL-C for very high-risk.

Recommended LLT Intensification

Early combination LLT helps achieve LDL-C goals.

Inclisiran: Overview

Inclisiran: siRNA therapy for sustained LDL-C reduction.

Inclisiran: Efficacy & safety

Inclisiran lowers LDL-C with favourable safety profile.

Real-world evidence

Reviews global and Indian real-world data demonstrating Inclisiran’s effectiveness, high adherence, and consistent LDL-C goal achievement.

LDLc and Risk Video

Assess Risk easily by using our calculators to risk profile your patient.

Lp(a) & LDL-C

Lp(a) is much more atherogenic than LDL; raises CV risk even at low LDL-C.

Lp(a) testing Guidelines

Guidelines recommend at least one Lp(a) test for all adults and high-risk patients.

Significance of Lp(a) testing

Lp(a) testing identifies hidden CV risk

Lp(a) & CVD risk

Elevated Lp(a) independently increases risk of CVD, stroke, and mortality.

Understanding Lp(a) Structure & Pathophysiology

Lp(a) is genetically determined, pro-atherogenic, and varies by ethnicity.